Poisoning and Toxic Effects of Drugs without MCC: Inpatient Reimbursement Overview

DRG 918 addresses hospital admissions for poisoning and toxic effects of drugs without Major Complication or Comorbidity. It defines the clinical scope for reimbursement and determines grouping for Medicare inpatient payment under the prospective payment system.

Customize your policy alerts

Sign up for drg 918 policy alerts

Get alerted when payer policies referencing 918 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

DRG 918 Overview

DRG 918 covers inpatient admissions for poisoning and toxic effects of drugs when no Major Complication or Comorbidity is present. It includes patients treated for drug overdoses or adverse toxic reactions that do not meet higher severity thresholds. This DRG matters for Medicare payment because it groups similar resource-use cases for standardized reimbursement under the inpatient prospective payment system. Proper assignment affects hospital payment and case mix reporting.

Clinical Trials

Acute emergency intervention trials: randomized or observational studies testing different immediate management strategies for patients hospitalized with drug poisoning or toxic effects, such as timing and use of decontamination methods, antidote administration protocols, or airway and hemodynamic support bundles. These studies typically enroll adult and pediatric inpatients presenting to emergency departments with confirmed or suspected overdose/toxicity and compare short-term outcomes like time to stabilization, need for ICU care, and in-hospital mortality. Results inform clinicians about best practices in the acute stabilization phase and help payers understand resource utilization drivers (e.g., ICU admission, antidote costs) for this DRG.
Comparative effectiveness and safety studies of antidote and supportive care strategies: prospective cohort studies or pragmatic trials comparing different antidotes, dosing regimens, duration of monitoring, or adjunctive therapies in subgroups defined by agent class (e.g., opioids, benzodiazepines, acetaminophen) and comorbidity burden. These investigations focus on clinically relevant endpoints such as organ failure rates, length of stay, readmission for recurrent toxicity, and adverse events related to interventions, enrolling patients across wards and critical care units. Findings guide evidence-based protocol development, enable hospitals to standardize care pathways, and assist payers in evaluating cost-effectiveness of specific treatments and monitoring strategies for reimbursement and coverage policies.
Post-discharge outcomes and prevention research: longitudinal observational studies and interventional trials targeting transition-of-care and secondary prevention in survivors of poisoning, including programs for substance use disorder referral, mental health follow-up, medication safety education, and monitoring for delayed toxic effects. These studies enroll patients discharged after an acute toxic exposure and measure outcomes such as 30- and 90-day readmission, repeat overdose, engagement in outpatient treatment, and long-term functional status. Results are important to providers aiming to reduce recurrent events and to payers interested in downstream cost savings from reduced readmissions and improved outpatient care coordination for this high-risk population.

Wound Debridements for Injuries with MCC: Inpatient Reimbursement Overview

902-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-CC

Wound Debridements for Injuries with CC: Inpatient Reimbursement Overview

903-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITHOUT-CC-MCC

Wound Debridements for Injuries without CC/MCC: Inpatient Reimbursement Overview

904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

905-SKIN-GRAFTS-FOR-INJURIES-WITHOUT-CC-MCC

Skin Grafts for Injuries without CC/MCC: Inpatient Reimbursement Overview

906-HAND-PROCEDURES-FOR-INJURIES

Hand Procedures for Injuries: Inpatient Reimbursement Overview

907-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-MCC

Other O.R. Procedures for Injuries with MCC: Inpatient Reimbursement Overview

908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

909-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITHOUT-CC-MCC

Other O.R. Procedures for Injuries without CC/MCC: Inpatient Reimbursement Overview

913-TRAUMATIC-INJURY-WITH-MCC

Traumatic Injury with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 19

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical Trials

Acute emergency intervention trials: randomized or observational studies testing different immediate management strategies for patients hospitalized with drug poisoning or toxic effects, such as timing and use of decontamination methods, antidote administration protocols, or airway and hemodynamic support bundles. These studies typically enroll adult and pediatric inpatients presenting to emergency departments with confirmed or suspected overdose/toxicity and compare short-term outcomes like time to stabilization, need for ICU care, and in-hospital mortality. Results inform clinicians about best practices in the acute stabilization phase and help payers understand resource utilization drivers (e.g., ICU admission, antidote costs) for this DRG.
Comparative effectiveness and safety studies of antidote and supportive care strategies: prospective cohort studies or pragmatic trials comparing different antidotes, dosing regimens, duration of monitoring, or adjunctive therapies in subgroups defined by agent class (e.g., opioids, benzodiazepines, acetaminophen) and comorbidity burden. These investigations focus on clinically relevant endpoints such as organ failure rates, length of stay, readmission for recurrent toxicity, and adverse events related to interventions, enrolling patients across wards and critical care units. Findings guide evidence-based protocol development, enable hospitals to standardize care pathways, and assist payers in evaluating cost-effectiveness of specific treatments and monitoring strategies for reimbursement and coverage policies.
Post-discharge outcomes and prevention research: longitudinal observational studies and interventional trials targeting transition-of-care and secondary prevention in survivors of poisoning, including programs for substance use disorder referral, mental health follow-up, medication safety education, and monitoring for delayed toxic effects. These studies enroll patients discharged after an acute toxic exposure and measure outcomes such as 30- and 90-day readmission, repeat overdose, engagement in outpatient treatment, and long-term functional status. Results are important to providers aiming to reduce recurrent events and to payers interested in downstream cost savings from reduced readmissions and improved outpatient care coordination for this high-risk population.

Wound Debridements for Injuries with MCC: Inpatient Reimbursement Overview

902-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-CC

Wound Debridements for Injuries with CC: Inpatient Reimbursement Overview

903-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITHOUT-CC-MCC

Wound Debridements for Injuries without CC/MCC: Inpatient Reimbursement Overview

904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

905-SKIN-GRAFTS-FOR-INJURIES-WITHOUT-CC-MCC

Skin Grafts for Injuries without CC/MCC: Inpatient Reimbursement Overview

906-HAND-PROCEDURES-FOR-INJURIES

Hand Procedures for Injuries: Inpatient Reimbursement Overview

907-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-MCC

Other O.R. Procedures for Injuries with MCC: Inpatient Reimbursement Overview

908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

909-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITHOUT-CC-MCC

Other O.R. Procedures for Injuries without CC/MCC: Inpatient Reimbursement Overview

913-TRAUMATIC-INJURY-WITH-MCC

Traumatic Injury with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 19

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Poisoning and Toxic Effects of Drugs without MCC: Inpatient Reimbursement Overview

Sign up for drg 918 policy alerts

DRG 918 Overview

Poisoning and Toxic Effects of Drugs without MCC: Inpatient Reimbursement Overview

Sign up for drg 918 policy alerts

DRG 918 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References